- Home
- DEA vs ANIP Comparison
DEA vs ANIP Comparison
Compare DEA & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEA
- ANIP
- Stock Information
- Founded
- DEA 2011
- ANIP 2001
- Country
- DEA United States
- ANIP United States
- Employees
- DEA N/A
- ANIP N/A
- Industry
- DEA Real Estate Investment Trusts
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- DEA Real Estate
- ANIP Health Care
- Exchange
- DEA Nasdaq
- ANIP Nasdaq
- Market Cap
- DEA 844.3M
- ANIP 1.5B
- IPO Year
- DEA 2015
- ANIP N/A
- Fundamental
- Price
- DEA $20.23
- ANIP $71.53
- Analyst Decision
- DEA Hold
- ANIP Strong Buy
- Analyst Count
- DEA 4
- ANIP 8
- Target Price
- DEA $29.06
- ANIP $80.13
- AVG Volume (30 Days)
- DEA 878.1K
- ANIP 387.2K
- Earning Date
- DEA 04-29-2025
- ANIP 05-09-2025
- Dividend Yield
- DEA 4.80%
- ANIP N/A
- EPS Growth
- DEA N/A
- ANIP N/A
- EPS
- DEA 0.41
- ANIP N/A
- Revenue
- DEA $314,385,000.00
- ANIP $614,376,000.00
- Revenue This Year
- DEA $6.87
- ANIP $27.68
- Revenue Next Year
- DEA $7.97
- ANIP $7.74
- P/E Ratio
- DEA $49.14
- ANIP N/A
- Revenue Growth
- DEA 6.82
- ANIP 26.20
- 52 Week Low
- DEA $19.33
- ANIP $52.50
- 52 Week High
- DEA $36.31
- ANIP $73.72
- Technical
- Relative Strength Index (RSI)
- DEA 36.84
- ANIP 59.87
- Support Level
- DEA $19.86
- ANIP $68.50
- Resistance Level
- DEA $21.33
- ANIP $73.72
- Average True Range (ATR)
- DEA 0.71
- ANIP 2.29
- MACD
- DEA 0.19
- ANIP -0.08
- Stochastic Oscillator
- DEA 44.97
- ANIP 64.22
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.